Celltrion Could Post Solid 2026 Earnings Growth -- Market Talk

Dow Jones03-17

0715 GMT - Celltrion could post strong earnings growth in 2026, driven by solid revenue contributions from a newly acquired plant in the U.S., DB Securities's Myoung-Sun Lee says. The South Korean biosimilar company's operating profit could jump 42% to 1.657 trillion won, with revenue up 26%, this year, the DB analyst writes in a note. The biologics facility in Branchburg, N.J., which Celltrion recently acquired from Eli Lilly, is set to generate a total of 680 billion won in revenue over three years starting in 2Q of 2026, Lee says. He views Celltrion as the most investor-friendly among local peers, citing a plan to cancel 9.1 million treasury shares valued at 1.927 trillion won. (kwanwoo.jun@wsj.com)

(END) Dow Jones Newswires

March 17, 2026 03:15 ET (07:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620944984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 15:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620944984","market":"us","top_or_hot":-1,"title":"Celltrion Could Post Solid 2026 Earnings Growth -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0715 GMT - Celltrion could post strong earnings growth in 2026, driven by solid revenue contributions from a newly acquired plant in the U.S., DB Securities's Myoung-Sun Lee says. The South Korean biosimilar company's operating profit could jump 42% to 1.657 trillion won, with revenue up 26%, this year, the DB analyst writes in a note. The biologics facility in Branchburg, N.J., which Celltrion recently acquired from Eli Lilly, is set to generate a total of 680 billion won in revenue over three years starting in 2Q of 2026, Lee says. He views Celltrion as the most investor-friendly among local peers, citing a plan to cancel 9.1 million treasury shares valued at 1.927 trillion won. (kwanwoo.jun@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 03:15 ET (07:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celltrion Could Post Solid 2026 Earnings Growth -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelltrion Could Post Solid 2026 Earnings Growth -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-17 15:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0715 GMT - Celltrion could post strong earnings growth in 2026, driven by solid revenue contributions from a newly acquired plant in the U.S., DB Securities's Myoung-Sun Lee says. The South Korean biosimilar company's operating profit could jump 42% to 1.657 trillion won, with revenue up 26%, this year, the DB analyst writes in a note. The biologics facility in Branchburg, N.J., which Celltrion recently acquired from Eli Lilly, is set to generate a total of 680 billion won in revenue over three years starting in 2Q of 2026, Lee says. He views Celltrion as the most investor-friendly among local peers, citing a plan to cancel 9.1 million treasury shares valued at 1.927 trillion won. (kwanwoo.jun@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 03:15 ET (07:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"POST","symbol_name":"Post Holdings","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620944984","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620944984","pubTimestamp":1773731700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0715 GMT - Celltrion could post strong earnings growth in 2026, driven by solid revenue contributions from a newly acquired plant in the U.S., DB Securities's Myoung-Sun Lee says. The South Korean biosimilar company's operating profit could jump 42% to 1.657 trillion won, with revenue up 26%, this year, the DB analyst writes in a note. The biologics facility in Branchburg, N.J., which Celltrion recently acquired from Eli Lilly, is set to generate a total of 680 billion won in revenue over three years starting in 2Q of 2026, Lee says. He views Celltrion as the most investor-friendly among local peers, citing a plan to cancel 9.1 million treasury shares valued at 1.927 trillion won. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"POST":"Post Holdings"},"translate_title":"赛特瑞恩2026年盈利可能实现稳健增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1.5},"content_text":"0715 GMT - Celltrion could post strong earnings growth in 2026, driven by solid revenue contributions from a newly acquired plant in the U.S., DB Securities's Myoung-Sun Lee says. The South Korean biosimilar company's operating profit could jump 42% to 1.657 trillion won, with revenue up 26%, this year, the DB analyst writes in a note. The biologics facility in Branchburg, N.J., which Celltrion recently acquired from Eli Lilly, is set to generate a total of 680 billion won in revenue over three years starting in 2Q of 2026, Lee says. He views Celltrion as the most investor-friendly among local peers, citing a plan to cancel 9.1 million treasury shares valued at 1.927 trillion won. (kwanwoo.jun@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 03:15 ET (07:15 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620944984","isCrawlerRequest":true}